How COVID-19 increased decentralized clinical trial adoption | Greg Licholai, PRA Health Sciences

In this exclusive interview we sat down with Greg Licholai, Chief Medical Information Officer at PRA Health Sciences, to discuss the impacts of COVID-19 on healthcare and drug development and whether these changes are temporary or permanent.

Speaking to Andy Burrows, Head of Content at Informa Connect Life Sciences, Licholai goes on to explore how one impact within the clinical trial space is the increased adoption of decentralized trials, explaining the current FDA and regulatory position, as well as what sponsors should be looking for in terms of partners for such trials.